EGFR-Directed Therapy in Lung Cancer

— —

So Yeon Kim (Yale School of Medicine, Connecticut) Daniel B. Costa (Harvard Medical School, Massachusetts)

EGFR-Directed Therapy in Lung Cancer

So Yeon Kim (Yale School of Medicine, Connecticut), Daniel B. Costa (Harvard Medical School, Massachusetts), Daisuke Shibahara (Harvard Medical School, Massachusetts) , Susumu Kobayashi (Harvard Medical School, Massachusetts)

$32.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Cambridge University Press
26 January 2023

Medical diagnosis; Oncology; Respiratory medicine

Series: Elements in Molecular Oncology

Summary
Details

Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).

By: So Yeon Kim (Yale School of Medicine Connecticut), Daniel B. Costa (Harvard Medical School, Massachusetts), Daisuke Shibahara (Harvard Medical School, Massachusetts), Susumu Kobayashi (Harvard Medical School, Massachusetts), Balazs Halmos (Albert Einstein College of Medicine, New York)
Imprint: Cambridge University Press
Country of Publication: United Kingdom
Dimensions: Height: 228mm, Width: 152mm, Spine: 3mm
Weight: 80g
ISBN: 9781009342308
ISBN 10: 1009342304
Series: Elements in Molecular Oncology
Pages: 75
Publication Date: 26 January 2023
Audience: General/trade , ELT Advanced
Format: Paperback
Publisher's Status: Active